Glycosylation Site-Specific Analysis of Clade C HIV-1 Envelope Proteins by Go, Eden P. et al.
Glycosylation Site-Specific Analysis of Clade C HIV-1 Envelope
Proteins
Eden P. Go1, Qing Chang1, Hua-Xin Liao2, Laura L. Sutherland2, S. Munir Alam2, Barton F.
Haynes2, and Heather Desaire1,*
1Department of Chemistry, University of Kansas, Lawrence, KS, 66045
2Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, 22270
Abstract
The extensive glycosylation of HIV-1 envelope proteins (Env), gp120/gp41, is known to play an
important role in evasion of host immune response by masking key neutralization epitopes and
presenting the Env glycosylation as “self” to the host immune system. The Env glycosylation is
mostly conserved but continues to evolve to modulate viral infectivity. Thus, profiling Env
glycosylation and distinguishing interclade and intraclade glycosylation variations are necessary
components in unraveling the effects of glycosylation on Env’s immunogenicity. Here, we describe
a mass spectrometry-based approach to characterize the glycosylation profiles of two rVV-expressed
clade C Envs by identifying the glycan motifs on each glycosylation site and determining the degree
of glycosylation site occupancy. One Env is a wild-type Env, while the other is a synthetic
“consensus” sequence (C.CON). The observed differences in the glycosylation profiles between the
two clade C Envs show that C.CON has more unutilized sites and high levels of high mannose
glycans; these features mimic the glycosylation profile of a Group M consensus immunogen, CON-
S. Our results also reveal a clade-specific glycosylation pattern. Discerning interclade and intraclade
glycosylation variations could provide valuable information in understanding the molecular
differences among the different HIV-1 clades and in designing new Env-based immunogens.
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Introduction
Among the distinct HIV-1 clades that have expanded worldwide, clade C infection is currently
one of the fastest growing HIV-1 infections1–3. Indeed, it accounts for more than 50% of all
global infections with 94% of HIV/AIDS clade C cases in sub-Saharan Africa4,5. Clade C
viruses in general have unique biological and immunological properties that include ease of
transmission6, exclusive CCR5 tropism during early infection7,8, sensitivity to neutralization
from clade C serum donors9,10, and resistance to neutralization by carbohydrate binding
antibody, 2G12, and by gp41 specific antibody, 2F59,11,12. Additionally, clade C Envs have
unique molecular features, including highly conserved V3 region compared to clade B11,13,
high amino acid sequence variability in the C3 region, a greater degree of amphipathicity of
the α-2 helix14, shorter V1–V4 loops for better neutralization sensitivity15, and shorter gp120
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early transmitted viruses10,11. These distinct molecular and immunological clade C Env
features illustrate the relevance of correlating the clade-specific structural differences with the
Env’s immunological properties. Establishing the relationship between clade-specific Env’s
immunological properties and structural elements could provide fundamental knowledge about
efficacious design of future HIV vaccine candidates.
One important molecular and structural feature of the Env that needs significantly more
attention is the N-glycosylation profiles of Env. Env glycosylation is fundamental in every
aspect of HIV biology that spans from proper Env folding and processing16,17, virus
transmission10,18–20, and immune evasive mechanisms21–23. There are at least potential 24
N-linked glycosylation sites for a given Env that can be populated with high mannose, hybrid,
or a highly diverse array of complex glycans24–28. The site utilization is known to vary within
isolates and across different clades allowing the global glycosylation to evolve to maintain the
glycan shield and facilitate viral transmission and dissemination23,29,30. Thus, the systematic
analysis of the glycosylation profiles of Env could provide valuable insights in designing good
Env immunogens.
An important step towards a systematic analysis of the glycosylation profiles of Env
immunogen is to identify and compare distinct intraclade and interclade Env glycosylation
profiles. A detailed characterization of the glycan patterns and determining the extent of site
occupancy of potential N-glycosylation (PNG) sites are critical steps in elucidating certain
glycosylation trends that influence the immunogenic and antigenic properties of Envs. And
given the importance of glycosylation in HIV pathogenesis, molecular insights provided by
glycosylation profiling are potentially useful in HIV vaccine development.
Recently, we have shown by a glycopeptide-based mass mapping approach that Envs’
glycosylation correlates with their immunological response27,28. We evaluated two
recombinant Env immunogens- one derived from the Group M HIV-1 consensus (CON-S
ΔCFI gp140) and one derived from a clade B primary isolate (JR-FL ΔCF gp140) and found
that the better Env immunogen (CON-S) has predominantly high mannose glycans populating
the region surrounding the immunodominant V3 region and has more unutilized glycosylation
sites throughout the protein. While the CON-S glycosylation profile provides one example of
the glycosylation profile of a good Env immunogen, several questions still remain. 1) Is the
glycosylation profile displayed by CON-S a central glycosylation pattern for all consensus Env
immunogens? 2) How do intraclade and interclade glycosylation profiles between Env
immunogens vary? To address these questions it is necessary to examine distinctive
glycosylation patterns of Env immunogens derived from other clades, including those from a
clade consensus, and determine interclade and intraclade glycosylation trends.
Towards this goal, we characterized the glycosylation profile of two clade C recombinant Envs
using the same glycopeptide-based mass analysis approach described in our previous
study27,28. The clade C Envs are derived from immunogens expressing clade C consensus
sequence, C.CON, and a clade C primary isolate sequence, C.97ZA012. Comparison of the
glycosylation profiles of the clade C Envs reveals the following characteristic glycosylation
profile - the consensus protein, C.CON, has a high level of high mannose glycans and a high
degree of unutilized glycosylation sites compared to C.97ZA012. Our analysis also shows that
both C.CON and C.97ZA012 share a common glycosylation pattern in the C2 and C3 regions
where predominantly high mannose glycans are observed. This glycosylation profile could
possibly influence the local Env structural conformation in these regions and may explain the
increased infectivity in clade C viruses. Comparison of the glycosylation profiles of Envs of
the same clade provides information on intraclade variations of glycosylation that help to
modulate the intrinsic clade-specific molecular, structural, and immunological properties.
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Ammonium bicarbonate, Trizma@ hydrochloride, Trizma@ base, ethylenediaminetetraacetic
acid (EDTA), acetic acid, HPLC grade acetonitrile (CH3CN) and methanol (CH3OH), 2,5-
dihydroxybenzoic acid (DHB), urea, α-cyano-4-hydroxycinnamic acid (α-CHCA),
iodoacetamide (IAA), dithiothreitol (DTT), and formic acid were purchased from Sigma (St.
Louis, MO). Water was purified using a Millipore Direct-Q3 Water Purification System
(Billerica, MA). Sequencing grade trypsin (Tp), proteomics grade N-Glycosidase F (PNGase
F) from Elizabethkingia meningosepticum, and glycerol-free PNGase F from Flavobacterium
meningosepticum were obtained from Promega (Madison, WI), Sigma (St. Louis, MO), and
New England BioLabs (Ipswich, MA), respectively.
Expression and Purification of HIV-1 Subtype C Envelope Proteins
C.CON and C.97ZA012 envelope proteins were obtained from the Duke Human Vaccine
Research Institute in Durham N.C. These proteins were constructed with internal deletions,
which generate marked improvement in oligomerization and immunogenicity31. Both Envs
were expressed and purified as described in literature32,33. Briefly, recombinant vaccinia
viruses (rVVs) expressing C.CON gp140 ΔCF and C.97ZA012 gp140 ΔCFI genes were used
for production of soluble Envs34,35. For batch production of recombinant Envs, Envs were
produced by infecting 293T cells with rVVs. The 293T cells were cultured in Dulbecco
modified Eagle medium (DMEM; Invitrogen Corp, Carlsbad, CA) supplemented with 10%
fetal calf serum in T150 tissue culture flasks and were grown to confluence at a multiplicity
of infection (MOI) of about one before infecting with rVVs. At two hours postinfection, the
cell culture was washed with serum free DMEM and the infection was allowed to proceed for
72 hours. Recombinant Envs were then purified from supernatants of rVV-infected 293T cell
cultures using Galanthus nivalis lectin-agarose (Vector Labs, Burlingame, CA) column
chromatography and stored at −70°C until use. A typical batch production of clade C Envs
(using 30 T-150 TC flasks) would yield ~600–800 µg of protein. Protein concentration was
determined by absorbance. Purified recombinant envelope proteins were concentrated for MS-
based glycosylation analysis.
Digestion of envelope proteins
Details of protein digestion have been described elsewhere27. Briefly, samples containing 200
µg of the HIV-1 Envs, with protein concentration >4 mg/mL, were denatured with 6M urea in
100 mM tris buffer (pH 8.5) containing 3 mM EDTA. The proteins were reduced and alkylated
with 10 mM DTT and 15 mM IAA at RT, respectively, and were digested at 37°C with trypsin
at a protein:enzyme ratio of 30:1 (w/w) overnight, followed by a second trypsin digestion under
the same conditions. The resulting HIV envelope glycoprotein digest was either subjected to
off-line reversed-phase high performance liquid chromatography (RP-HPLC) fractionation for
MALDI or RP-HPLC/ESI-FTICR MS analyses27,36. To ensure reproducibility and reliability
of our method, protein digestion was performed three times on different days with Env samples
obtained from the same batch and analyzed with the same experimental procedure. In addition,
Env samples obtained from two different batches with different protein concentration were
also digested and analyzed to determine lot-to-lot variations in glycosylation profile.
N-Deglycosylation
The Env deglycosylation experiment for MALDI MS analysis was performed as described
elsewhere27. Briefly, glycopeptide enriched fractions were collected from an HPLC, as
described above, and the glycans were released by adding 12 µL of 20 mM NH4HCO3 (pH
8.5) and 4 µL of diluted PNGase F solution (500 units/mL). The reaction was incubated
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overnight at 37°C and was stopped by heating the sample to 100°C. The resulting solution was
subsequently analyzed by MALDI MS. Deglycosylation experiment for LC/ESI-FTICR MS
analysis was performed by incubating ~50 µg of the Env with 1 µL of PNGase F solution (≥
4500 units/mL) for a week at 37°C. Deglycosylated Env proteins were digested at 37°C with
trypsin using the same digestion procedure described above. The resulting tryptic digest was
analyzed by LC/ESI-FTICR MS.
Mass Spectrometry
MALDI MS and MS/MS experiments were performed on an Applied Biosystems 4700
Proteomics Analyzer mass spectrometer (Foster City, CA) operated in the positive ion mode.
Samples were prepared by mixing equal volumes (1 µL each) of the analyte and matrix
solutions in a microcentrifuge tube, then immediately deposited on a MALDI plate, and
allowed to dry in air. Matrix used for the experiment consists of a 1:1 mixture of 10 mg/mL
each of α-CHCA and DHB. Samples were irradiated with an ND-YAG laser (355 nm) operated
at 200 Hz. High resolution mass spectra were acquired in the reflectron mode and were
generated by averaging 3000 individual laser shots into a single spectrum. Each spectrum was
accumulated from 60 shots at 50 different locations within the MALDI spot. The laser intensity
was optimized to obtain adequate signal-to-noise (S/N) ratio and resolution for each sample.
MALDI MS/MS data were acquired using a collision energy of 1 kV with air as collision gas.
LC/ESI-FTICR MS and MS/MS experiments were performed using a hybrid linear ion-trap
Fourier transform ion cyclotron resonance mass spectrometer (LTQ-FT, ThermoScientific, San
Jose, CA) directly coupled to Dionex UltiMate capillary LC system (Sunnyvale, CA) equipped
with a FAMOS well plate autosampler. Mobile phases utilized for the experiment consisted of
solvent A: 99.9% deionized H2O + 0.1% formic acid and solvent B: 99.9 % CH3CN + 0.1%
formic acid. Five microliters of the sample was injected onto C18 PepMap™ 300 column (300
µm i.d. × 15 cm, 300 Å, LC Packings, Sunnyvale, CA) at a flow rate of 5 µL/min. The following
CH3CN/H2O multistep gradient was used: 5% mobile phase B for 5 min, followed a linear
increase to 40% B in 50 min a linear increase to 90% B in 10 min. The column was held at
95% B for 10 minutes before re-equilibration. A short wash and blank run were performed
between every sample to ensure no sample carry-over. The ESI source was operated in the
following conditions: source voltage of 2.8 kV, capillary temperature of 200°C, and capillary
voltage of 46 V. Data were collected in a data-dependent fashion in which the five most intense
ions in an FT scan were sequentially and dynamically selected for subsequent collision-induced
dissociation (CID) in the LTQ linear ion trap using a normalized collision energy of 30% and
a 3 minute dynamic exclusion window.
Glycopeptide Identification
Glycopeptide compositions with singly utilized glycosylation site were elucidated using the
web-based-tools, GlycoPep DB37 and GlycoPep ID38. Details of the analysis for glycopeptides
have been described previously27,37,38. Briefly, compositional analysis was performed by
identifying the peptide portion of a glycopeptide of interest from MS and MS/MS spectra
generated from MALDI MS and LC/ESI-FTICR MS analyses. Peptide portions were
elucidated from characteristic signature fragment ions of the cross-ring cleavages, 0,2X
or 0Y1 ions in the MS/MS data using GlycoPep ID. Once the peptide portion is identified,
plausible glycopeptide compositions are obtained from MS data using GlycoPep DB. For
glycopeptides with multiply utilized glycosylation sites, experimental masses of singly charged
glycopeptide ions from MS data were submitted to GlycoMod39. This program calculates
plausible glycopeptide compositions from the set of experimental mass values entered by the
user and compares these mass values with theoretical mass values, then generates a list of
plausible glycopeptide compositions within a specified mass error. Plausible glycopeptide
compositions in GlycoMod were deduced by providing the mass of the singly charged
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glycopeptide ion, enzyme, protein sequence, cysteine modification, mass tolerance, and the
possible types of glycans present in the glycopeptide. Plausible glycopeptide compositions
were manually confirmed and validated using MS/MS data.
Peptide Identification
Non-glycosylated peptides were identified by searching raw MS/MS data acquired on the
hybrid LTQ FTICR mass spectrometer against a custom HIV database with 107 protein entries,
obtained from the Los Alamos HIV sequence database (http://www.hiv.lanl.gov/content),
using Mascot (Matrix Science, London, UK, version 2.2.04). The peak list was extracted from
raw files using BioWorksBrowser (Thermo Electron Corporation, version 3.5). DTA files were
searched specifying the following parameters: (a) enzyme: trypsin, (b) missed cleavage: 2, (c)
fixed modification: carbamidomethyl, (d) variable modification: methionine oxidation, and
carbamyl, (e) peptide tolerance of 0.8 Da, and (f) MS/MS tolerance of 0.4 Da. Peptides
identified from Mascot search were manually validated from MS/MS spectra to ensure major
fragmentation ions (b and y ions) were observed especially for peptides generated from PNGase
treated Envs containing potential N to D conversions.
Results
C.CON and C.97ZA012 Envs
We evaluated the glycosylation profiles of two clade C Env immunogens, specifically, one
protein is a synthetic Env sequence, C.CON, generated from the alignment of HIV-1 clade C
gene sequences available from the 2003 Los Alamos HIV-1 Database; the other protein is a
primary isolate Env, C.97ZA012, from an HIV-1 strain from South Africa12. Both Envs were
constructed with shortened variable loops (V1–V5), and deletions of the cleavage site (C),
fusion domain (F), (ΔCF) for C.CON and deletions of the cleavage site (C), fusion domain (F),
the immunodominant region (I) in the transmembrane region (ΔCFI) for C.97ZA01232,33. The
two C Envs are designated as C.CON gp140ΔCF and C.97ZA012 gp140ΔCFI. It should be
noted that immunology data showed no apparent difference between gp140ΔCF and
gp140ΔCFI constructs in terms of eliciting antibody response33. The full sequence alignment
of C.CON gp140ΔCF and C.97ZA012 gp140ΔCFI with potential N-linked glycosylation
(PNG) sites in red is shown in Figure 1. For consistency, the amino acid numbering positions
were based on the reference strain, HXB2 (SwissProt accession number P04578). The protein
sequence of the two Envs differs by 17%, as determined from the protein sequence alignment
analysis tool, ClustalX40. There are 29 PNG sites for C.CON gp140ΔCF and 24 PNG sites for
C.97ZA012 gp140ΔCFI. Between the two clade C Envs, 22 PNG sites are highly conserved
and nine are not conserved as shown in green boxes (Figure 1). Conserved PNG sites are spread
throughout the Env sequence with eight PNG sites located in the hypervariable regions: V1
(N133, N139, and N156), V2 (N160 and N187), V3 (N301), and V4 (N386 and N397), and
14 conserved PNG sites located in the conserved regions: C1 (N88), C2 (N197, N230, N241,
N262, N276, and N289), C3 (N332, N339, and N356), and C4 (N442, and N448), and the
transmembrane (N625 and N637) regions. PNG sites that are not conserved shown in green
boxes in Figure 1 and are located in the C1, V2, C2, V4, V5, and transmembrane regions. For
simplicity, C.CON gp140ΔCF and C.97ZA012 gp140ΔCFI are referred as C.CON and wild-
type C, from here on and data presented in the following sections are from samples that were
processed and analyzed three times using the same batch. These analyses obtained reproducible
glycosylation profiles.
Glycosylation Analysis of C.CON and Wild-Type C Envs
To determine the glycosylation motifs on each glycosylation site as well as to identify
unutilized glycosylation sites, the Envs were denatured, reduced, and alkylated with IAA
before being subjected to an in-solution tryptic digestion. The resulting digest mixture was
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divided into two equal aliquots, with one aliquot analyzed by MALDI MS in both linear and
reflectron modes and the other by LC/ESI-FTICR MS. Before mass analysis, both aliquots
were subjected to reverse-phase HPLC to separate the glycopeptides from peptides. Similar to
our previous study27,28, the glycopeptide compositions and the glycosylation site occupancy
are unambiguously identified from tandem MS analysis and deglycosylation experiments in
combination with the web-based analysis tools, GlycoPep DB, GlycoPep ID, and GlycoMod.
A 100% glycosylation site coverage was obtained for both C.CON and wild-type C. Table 1
summarizes the glycosylation site coverage showing the identified tryptic peptides bearing
single and multiple potential N-linked glycosylation (PNG) sites (NXT/S) and their respective
glycosylation site occupancy. Table 1 shows that C.CON has a lower degree of glycosylation
site occupancy compared to wild-type C. These glycosylation sites are either fully or variably
unutilized. C.CON differs in the degree glycosylation site occupancy with wild-type C in the
following regions: at the end of the V2 loop, the V4 loop, and the transmembrane region.
Glycopeptides identified from MALDI MS and LC/ESI-FTICR MS analyses bear glycans
consisting of high mannose, hybrid, and complex type structures as shown in Table 2 (see
Supplementary Table for a complete list). The glycopeptides have either single or multiple
glycosylation sites. Figure 2A and Figure 3A show MALDI MS and LC/ESI-FTICR MS
spectra typical of a glycopeptide rich fraction. These data show glycopeptides with the singly
utilized glycosylation site found at the beginning of the V3 region for wild-type C (Figure 2A),
and the C4 and the transmembrane regions for C.CON (Figure 3A). A characteristic feature of
the mass spectra of glycopeptides with a singly utilized glycosylation site is a series of singly
charged peaks in MALDI MS or doubly/multiply charged peaks in LC/ESI-FTICR MS
separated by a mass difference equivalent to the mass of the monosaccharide units (hexose
(Hex), N-acetylglucosamine (HexNAc), fucose (Fuc), and sialic acid (NeuNAc)). These
characteristic patterns in the MS data helped identify ions that were likely glycopeptides.
For both MS techniques, compositions of glycopeptides with one glycosylation site were
elucidated from the fragmentation pattern of the glycopeptide peaks observed in the high
resolution mass spectra. The peptide portion and the glycan compositions were identified from
the MS/MS data (Figure 2B, Figure 3B, and 3C). The peptide portion was determined from
the characteristic glycosidic cleavages, 0,2X or Y1 ions (Figure 2B, Figure 3B, and 3C). Peptide
sequences identified from MALDI MS/MS were further validated from the MS and MS/MS
analysis of the deglycosylated glycopeptide fraction of interest (Figure 2C and 2D). A typical
MALDI MS spectrum of the deglycosylated fraction shows deglycosylated peptides with
potential N to D conversion depending on the site utilization (Figure 2C). Peptide sequences
were confirmed from the observed fragmentation pattern in MALDI MS/MS spectrum (Figure
2D). For glycopeptides with multiple glycosylation sites, glycopeptide compositions were
determined from GlycoMod using the data obtained from high resolution LC/ESI-FTICR MS
(Figure 4A) or MALDI MS in the linear mode (Figure 4C). Results from GlycoMod were
validated using the MS/MS data (Figure 4B). Overall, a total of 300 unique glycopeptide
compositions per Env were identified for both singly and multiply glycosylated glycopeptides.
The full list of the identified glycopeptides is included in the supplementary information.
Glycan Profile of C.CON and Wild-Type C Envs
The glycan compositions of the two clade C Envs were broadly grouped according to the type
of glycan found on each glycopeptide and were plotted in a bar graph. A glycopeptide could
have a single or multiple glycosylation sites. Each glycopeptide is represented with a bar or a
pair of bars corresponding to the glycan percentage of processed or high mannose glycans that
is arranged according to the Env sequence position. The following criteria was used to
determine the relative number of processed or high mannose glycans: “high mannose” includes
structures with 5–9 mannose units and “processed glycans” includes both hybrid and complex
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type structures with hexose (Hex) ≥3 and N-acetylglucosamine (HexNAc) ≥ 4 or Hex ≥ 4 and
HexNAc ≥ 327. Bar graphs showing the differential glycan profiles between the synthetic
consensus Env, C.CON, and wild-type C, are shown in Figure 5. Comparison of the glycan
profiles of wild-type C and C.CON shows similarities as well as differences throughout the
Env. The glycan profile of wild-type C and C.CON are different in the following glycosylation
sites in the corresponding Env regions: N275 and N289 in the C2 region, N301 in the V3 loop,
N339 in the C3 region, N386 at the beginning of the V4 loop, N442 in the C4 region. These
glycosylation sites have more high mannose glycans (%glycan ≥ 50) in C.CON compared to
wild-type C. On the other hand, the glycan profiles on the conserved glycosylation sites, N230,
N241, N262, and N332 in the C2 and C3 regions, for wild-type C and C.CON are the same.
These glycosylation sites are populated with high mannose glycans. Glycosylation site at N234
in C.CON was not present in wild-type C due to a mutation.
In an effort to determine the minimum concentration of Env needed for analysis and the
variations in glycosylation profile between batches of the same protein, glycosylation analysis
of C.CON from two different batches with different concentrations following the same
procedure described above was performed. One batch (C.CON #1) has a protein concentration
of 14.2 mg/mL and the other batch (C.CON #2) has a protein concentration of 2.16 mg/mL as
determined from their absorbance. These two batches were produced from different rVV-
infected 293T cell cultures. A 100% glycosylation coverage of the glycosylated peptides was
obtained for C.CON #1 and 48% for C.CON #2. Based on these results, and previous analyses
we have conducted on Envs with different initial concentrations, we determined that an initial
protein concentration >4 mg/mL is needed for complete coverage. This corresponds to a
concentration of about 28 µM. Due to these requirements, this type of analysis is well suited
for analyzing recombinant protein but possibly not well suited for analyzing Env isolated off
virions if present in low concentration.
To examine the variation in glycan profile between these samples, glycan profiles of the eight
most abundant glycopeptides in C.CON #1 were compared with the same eight most abundant
glycopeptides in C.CON #2. A bar graph showing the glycan profiles of C.CON #1 and C.CON
#2 in Figure 6 shows remarkably similar glycan profiles. The similarity of these profiles
reinforces the fact that differences in glycan profiles are not related to the analytical conditions,
the starting concentration of the sample, or the particular batch of cells used. Rather, differences
in the bar graphs, such as those in Figure 5 indicate fundamental differences in the proteins.
We have not yet tested whether or not changing the cell line that produces the protein would
change the glycosylation profile. However, it is fully reasonable to expect that a different cell
line could generate protein with modified glycosylation and that a modified glycoprotein may
have a different immunological response.
Discussion
Clade C is the most rapidly spreading form of HIV-1, and this is the first analysis of the glycan
profiles of any clade C Env protein. The data reported here extends our previous work in
comparing glycosylation profiles with immunogenicity data for two other Env immunogens.
It is well established that Env glycosylation is crucial in host immune regulation by affecting
protein conformation as well as masking key protein epitopes22,30,41–45. Thus, assessing the
differences and similarities in glycosylation between Env immunogens and distinguishing the
profiles that correlate to Env immunogenicity is important in the improvement of vaccine
design and efficacy. We established previously by a glycopeptide-based mass mapping
approach that a good immunogen has a glycosylation profile with higher levels of high mannose
glycans surrounding the immunogenic V3 region and higher levels of unutilized glycosylation
sites27. When compared with immunology data, such a glycosylation profile correlates to better
induction of both humoral and cellular immunity in small animal and primate models33,46.
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Clearly, how well an Env immunogen induces a potent immune response depends in part on
the number of PNG sites, the degree of glycosylation site occupancy, and the glycan motifs
populating each glycosylation site. However, these elements vary considerably between
isolates and across clades, due to the HIV genetic diversity14,47,48. Thus, evaluation of Env
glycosylation is in part crucial in establishing the utility of Env immunogens as potential
components of a vaccine regimen. As an important step in understanding the influence if
glycosylation to immunogenecity the following questions must be addressed: (1) What are the
interclade differences and similarities in the glycosylation profiles? (2) How does the
glycosylation profile of a group M global consensus (CON-S) differ from a clade-specific
consensus?
Interclade Variations in Glycosylation Site Occupancy and Env Immunogenecity
We characterized the glycosylation of two clade C Env immunogens to determine the variations
in glycosylation profiles and correlate our results with immunology data. We showed that
C.CON and wild-type C differ by 17% in amino acid sequence, which is well within the
interclade genetic variation (>15%)47. The relative difference in Env amino sequence
determines the number of PNG sites on the Env. In fact, for the collection of gp120 protein
sequences in the Los Alamos HIV sequence data repository, the number of PNG sites ranges
from 18–33, with a median of 2530,48. The relative variation in the number of PNG sites is due
to an insertion or deletion specifically in the hypervariable regions48. In general, a loss of a
PNG site and/or lesser degree of glycosylation site occupancy will impose lesser constraints
on neutralizing antibodies (NAbs) to access key neutralization epitopes. Our results show that
the consensus protein, C.CON, has more unutilized glycosylation sites compared to the wild-
type C (See Table 1). There are seven unutilized sites for C.CON and two for wild-type C.
Most of these unutilized glycosylation sites for both clade C Envs are conserved. Six of the
seven unutilized sites for C.CON and the two unutilized sites for wild-type C are variably
utilized. One of the seven unutilized sites for C.CON is not glycosylated at all. This non-
glycosylated site is located at N625 in the transmembrane region and the same site is utilized
in wild-type C. Glycosylation sites that are variably unutilized are located in the V1/V2 loops
(N133, N156, and N187), V4 loop (N386 and N397) and transmembrane region (N616) for
C.CON and in the V1/V2 region (N156 and N184) for wild-type C. Variably unutilized PNG
sites that are not conserved between the two Envs (shown in green boxes in Figure 1) are either
deleted or mutated in either C.CON or C.97ZA012. These PNG sites are located at N184 in
the V2 loop for wild-type C and at N616 in the transmembrane region for C.CON.
Corresponding glycosylation sites at N187 in wild-type C and at N616 in C.CON were deleted.
How these open glycosylation sites may influence the Env immunogenicity depend on their
location and their distribution in the Env structure. More unutilized glycosylation sites in
regions where neutralization epitopes are located would lead to better Env immunogenicity.
Indeed, removal of glycans in the variable loops is known to increase neutralization
sensitivity49. The variably unutilized glycosylation sites at N133, N156, and N187 for C.CON
and N156 and N184 for wild-type C lie at the base of the V1/V2 loop and are proximal to the
two disulfide bonds that define the V1/V2 loop. Glycosylation on these sites could affect the
flexibility as well as the orientation of the V1/V2 loop. Additionally, it has been proposed that
there is interaction between V1/V2 and V3 loops wherein glycans play a role in helping to
protect the CD4 binding site against NAbs50. Thus, absence of glycans in the V1/V2 loop
would make the CD4 binding site vulnerable to NAbs. Direct comparison of the glycosylation
site occupancy between C.CON and wild-type C in the V1/V2 loop shows difference in
glycosylation site occupancy at sites N133 and N187. Both of these sites are variably unutilized
in C.CON but fully utilized in wild-type C. While the wild-type C Env nominally has an extra
glycosylation site at N184 that is absent in C.CON, this site is only variably unutilized, which
significantly mitigates its impact. Clearly, C.CON is less glycosylated compared to wild-type
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C. Less glycosylation in the V1/V2 loop in C.CON promotes better accessibility of Abs to the
CD4 binding site.
Apart from the V1/V2 loop, there are two more variably unutilized PNG sites in C.CON at
N386 and N397 in the V4 loop. N386 is located at the base of the V4 loop and proximal to the
chemokine receptor binding site, while N397 is within the V4 loop51–55. The lack of glycans
at these sites could allow for better accessibility of antibodies to the critical CD4 induced
epitopes. Finally, the highly conserved glycosylation in the transmembrane region has been
reported to effectively shield the underlying epitopes in this region56. The lack of glycan at
N625 in C.CON could increase the neutralization sensitivity to this region, once it is exposed.
Interclade Variations in Glycan Profiles and Env Immunogenecity
While there is mounting evidence that the lack of glycans on PNG sites or the absence of a
PNG site is a good measure to differentiate a good immunogen from a poor immunogen, the
diverse array of glycans decorating the glycosylation sites can also be characterized and
correlated to the immunogenicity of different Envs. Indeed, the type of prevalent glycans on
each glycosylation site and how they are distributed throughout the Env could help define the
glycosylation pattern that potentially influences Env immunogenecity. This study takes a small
step toward unraveling the correlation between glycosylation profiles and immunogenicity by
comparing the profiles of two clade C proteins. MS analysis of the glycan profiles of wild-type
C and C.CON shows distinct difference in the glycan patterns between the clade C Envs (Figure
5). C.CON generally displays a higher population of high mannose glycans compared to wild-
type C in the C2 region, V3 loop, C3 region, V4 loop, and C4 region. When mapped onto the
gp120 structure, these glycosylation sites (N275, N289, N301, N339, N386, and N442) are
located in the outer domain of gp120 and are within the 2G129,11,12,57,58 and the IgG1 b12
binding sites59. Considering that high mannose glycans promote proper Env folding and
stabilize protein conformation60–62, it is likely that the glycosylation sites with high mannose
in C.CON provide conformational stability in this region. This stabilization could enhance the
ability of C.CON to elicit a wider breadth of NAbs to this region. This interclade variation in
glycosylation reflects a difference in structural conformation in this region between the two
clade C Envs. The higher level of high mannose glycans in C.CON indicates a highly
structurally conserved Env that in part correlates with its ability to induce wide breadth of
NAbs compared to wild-type C63.
Clade C Specific Glycosylation Patterns that Could Correlate to Enhanced Infectivity
In addition to the differences in the glycan profile between the two clade C Envs, four conserved
glycosylation sites in the C2 and C3 regions of C.CON and wild-type C have similar glycan
patterns, specifically at N230, N241, N262, and N332 which predominantly bear high mannose
glycans. Studies have shown that HIV-1, HIV-2, and SIV are transmitted efficiently to T-cells
when their respective Envs have high levels of high mannose glycans29. This process is
mediated by DC-SIGN and DC-SIGNR, which are calcium dependent C-type lectins that
facilitate HIV transmission and dissemination64,65. These C-type lectins have high affinity and
binding specificity to high mannose glycans66–69. With this precedent, it is possible that the
clade-specific glycan pattern in clade C Env observed in this study (mainly, the presence of
high mannose glycans in the C2 region) is responsible for efficient transmission of clade C
viruses through mediation by DC-SIGN and DC-SIGNR. This glycan profile is remarkably
conserved within clade C Env immunogens analyzed in this study and possibly important in
modulating clade C infectivity. While the role of this glycosylation pattern in the Env’s
immunology remains to be determined, future studies could focus in elucidating intraclade
glycosylation variations that modulate DC-SIGN binding and infectivity.
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Glycosylation Profile of Two Consensus Immunogens
How does the overall glycosylation profile of the clade consensus, C.CON, compare to the
group M consensus, CON-S? Figure 7A and 7B show a composite representation of the overall
glycosylation profile that includes the unutilized glycosylation sites as well as the glycan
profiles for CON-S, C.CON, and wild-type C. The data presented for CON-S were obtained
from our previous study27,28. Comparison of the overall glycosylation profiles reveals that
C.CON reflects a similar glycosylation pattern as CON-S. Both consensus Envs have high
levels of unutilized glycosylation sites and high levels of high mannose glycans surrounding
the immunogenic V3 region. CON-S has a higher number of total PNG sites and unutilized
glycosylation sites compared to C.CON (Figure 7A). Additionally, the unutilized glycosylation
sites and the respective distribution of these sites in the Env regions in C.CON follow a similar
trend observed in CON-S. These unutilized glycosylation sites are well conserved in both of
the consensus Envs, indicating a trend for more open glycosylation sites for good Env
immunogens.
When all glycosylation sites are considered for CON-S, C.CON, and wild-type C, C.CON has
higher levels of high mannose glycans than the clade-generic consensus Env, CON-S (Figure
7B). This difference likely reflects clade specific differences, where clade C proteins have
inherently more high mannose glycans in the C2 region. The fact that this is a clade-specific
difference is further supported by data that shows the clade C wild type Env protein had a much
higher level of high-mannose glycans, compared to the clade B wild-type Env protein, JR-FL
(data not shown.) Lastly, taking into consideration the glycan profiles between C.CON and
CON-S, the utilized glycosylation sites have high levels of high mannose glycans for both
consensus Env immunogens between the C2 region and the beginning of the C3 region. This
consensus Env glycosylation feature indicates that Env conformation in these regions is
conserved for both C.CON and CON-S. These data correlate well with immunology data where
both the clade consensus and group M consensus Env immunogens elicited wide breadth of
NAbs when used as vaccine components in small animal models63.
Conclusions
Mass spectrometry-based glycosylation profiling of two rVV expressed clade C HIV-1 Envs
described in this study provides an informative approach to differentiate glycosylation profiles
of Env immunogens. A combination of MALDI-MS and LC/ESI FTICR-MS with liquid
chromatography, tandem MS analyses, and web-based analysis tools were used to map the
glycan motifs as well as glycosylation site occupancy in a glycosylation site-specific fashion.
Our results show that the consensus protein, C.CON, has more unutilized glycosylation sites
and a high level of high mannose glycans in the region surrounding the immunodominant V3
loop but also in the C4 region and at the beginning of V4 loop. Interestingly, the glycosylation
profile of C.CON shows some degree of similarity to another consensus immunogen, CON-S,
derived from the global group M env sequence. The common glycosylation features between
C.CON and CON-S indicate that consensus Envs have similar functionally conserved Env
conformations and therefore similar immunogenicity63. It is also important to note that our
results also reveal a clade-specific glycosylation pattern in the C2 and the C3 regions.
While an effective vaccine against HIV infection remains elusive, considerable progress has
been made so far in understanding the immunopathogenesis of HIV. The Env is a major target
for vaccine design and one Env-based immunogen design strategy is delineating the Env
glycosylation and modifying the glycosylation to improve the breadth of NAb coverage27,44,
49,50,63,70–74. Thus, a systematic comparison of interclade and/or intraclade glycosylation
profiles between Env immunogens may prove useful in distinguishing a definitive
glycosylation patterns that positively contributes to Env’s immunogenicity and the knowledge
gained from this study will certainly enhance vaccine design,
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Sequence alignment of C.CON gp140 ΔCFI and C.97ZA012 gp140ΔCF. Dashes indicate gaps
in amino acid sequence and the location of the variable (V1–V5) and conserved (C1–C5)
regions are shown. Potential glycosylation sites are in red with difference in potential
glycosylation sites are boxed. To standardize the sequence positions, numbering was based on
the reference HIV strain, HXB2.
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A. MALDI MS spectrum of the glycopeptide rich fraction generated from the proteolytic digest
C.97ZA012 gp140ΔCF. B. MALDI MS/MS spectrum of the identified tryptic glycopeptide at
m/z 3307. C. MALDI MS of the PNGase-treated glycopeptide rich fraction shown in A. D.
MALDI MS/MS spectrum the deglycosylated peptide (m/z 1661, shown in C in the V3 region.
Note that peaks with asterisks(*) in A are glycopeptide peaks.
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A. LC/ESI-FTICR MS spectrum of the glycopeptide rich fraction showing two identified
glycopeptides in the C4 and the transmembrane region for C.CON gp140 ΔCFI. ESI-MS/MS
spectra showing the fragmentation pattern of the glycopeptides in the C4 region (B) and the
transmembrane region (C). Only one site is utilized. Note that peaks with asterisks(*) are
glycopeptide peaks.
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A. LC/ESI-FTICR MS spectrum of the doubly glycosylated peptide with one missed cleavage,
GPCNN241VSTVQCTHGIKPVVSTQLLLN262GSLAEKEIIIR, in the C2 region of C.
97ZA012 gp140ΔCF. B. ESI-MS/MS spectra showing the fragmentation pattern of the doubly
glycosylated peptide in A. C. MALDI MS spectrum of the doubly glycosylated peptide,
GPCNN241VSTVQCTHGIKPVVSTQLLLN262GSLAEK, in the C2 region of C.97ZA012
gp140ΔCF measured in the linear ion mode.
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Summary of glycan compositions (in percent) on the identified glycosylation site. Glycan
compositions were broadly categorized into two classes (see text). Unprocessed glycans
include high mannose glycans while processed glycans include hybrid and complex type
glycans.
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Glycan compositions (in percent) of the eight most abundant glycopeptides from C.CON gp140
ΔCF samples produced from two different batches.
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(A). Summary of glycosylation site occupancy for C.CON gp140ΔCF, C.97ZA012 gp140
ΔCFI, and CON-S gp140ΔCFI. Glycosylation site occupancy data for CON-S was obtained
from our previous study. (B). Composite distribution of the type of glycans in C.CON
gp140ΔCF, C.97ZA012 gp140ΔCFI, and CON-S gp140ΔCFI.
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Table 1
Tryptic glycopeptides detected by MALDI MS and LC/ESI-FTICR MS




A. Glycopeptides with fully utilized sites
  EVHNVWATHACVPTDPNPQEIVLEN88VTENFNMWK 1 1
  LTPLCVTLHCTN133ATFKNN139VTNDMNK 2 2
  CNN230K 1 1
  GPCNN241VSTVQCTHGIKPVVSTQLLLN262GSLAEK 2 2
  SEN275LTDNVK 1 1
  TIIVHLN289K 1 1
  SVEIVCTRPNN301NTR 1 1
  QAYCN332ISGSK 1 1
  WN339ETLKR 1 1
  LQENYNNN356K 1 1
  GEFFYCN386TTR 1 1
  LFNNN397ATEDETITLPCR 1 1
  AMYAPPIAGN442ITCK 1 1
  SN448ITGLLLVR 1 1
  DGGEDN462KTEEIFRPGGGNMK 1 1
  DQQLEIWN625MTWMEWDREISN637YTDTIYR 2 2
B. Glycopeptides with partially utilized sites
  N156CSFN160TTTEIR 2 1 and 2
  ENRN184NSN187NSEYILINCN197AST ITQACPK 3 2 and 3
C.CON gp140 ΔCF
A. Glycopeptides with fully utilized sites
  EVHNVWATHACVPTDPNPQEVVLEN88VTEHFNMWK 1 1
  LINCN197TSAITQACPK 1 1
  CNN230K 1 1
  TFN234GTGPCNN241VSTVQCTHGIKPVVSTQLLLN262GSLAEEEIIIR 3 3
  SEN275LTNNAK 1 1
  TIIVHLN289ESVEICTRPNN301NTR 2 2
  QAHN332ISSEDKWN339K 2 2
  LKEHPN356K/ LKEHPN356KTIK 1 1
  AMYAPPIAGN442ITCK 1 1
  SN448ITGLLLTR 1 1
  DGGKN461NTETFRPGGGDMR 1 1
  EISN637YTDTIYR 1 1
B. Glycopeptides with partially utilized sites
  LTPLCVTLN130CTN133ATN136ATNTMGEIK 3 2
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Glycopeptide Number of PotentialGlycosylation Sites
Number of
Utilized Sites
  N156CSFN160ITELR 2 1 and 2
  LDIVPLNEN187NSYR 1 0 and 1
  GEFFYCN386TSK 1 0 and 1
  LFN392STYN397STN411STITLPCR 3 2 and 3
  LICTTAVPWN611SSWSN616K 2 1
C. Nonglycosylated Peptide
 SQEDIWDN625MTWMQWDR 1 0





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































J Proteome Res. Author manuscript; available in PMC 2010 September 1.
